BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 29643249)

  • 1. Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs.
    Bricault CA; Kovacs JM; Badamchi-Zadeh A; McKee K; Shields JL; Gunn BM; Neubauer GH; Ghantous F; Jennings J; Gillis L; Perry J; Nkolola JP; Alter G; Chen B; Stephenson KE; Doria-Rose N; Mascola JR; Seaman MS; Barouch DH
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29643249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.
    Nkolola JP; Peng H; Settembre EC; Freeman M; Grandpre LE; Devoy C; Lynch DM; La Porte A; Simmons NL; Bradley R; Montefiori DC; Seaman MS; Chen B; Barouch DH
    J Virol; 2010 Apr; 84(7):3270-9. PubMed ID: 20053749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.
    Bricault CA; Kovacs JM; Nkolola JP; Yusim K; Giorgi EE; Shields JL; Perry J; Lavine CL; Cheung A; Ellingson-Strouss K; Rademeyer C; Gray GE; Williamson C; Stamatatos L; Seaman MS; Korber BT; Chen B; Barouch DH
    J Virol; 2015 Mar; 89(5):2507-19. PubMed ID: 25540368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
    Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
    van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
    Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
    J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens.
    Seaman MS; Leblanc DF; Grandpre LE; Bartman MT; Montefiori DC; Letvin NL; Mascola JR
    Virology; 2007 Oct; 367(1):175-86. PubMed ID: 17599382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination.
    Luo Z; Ren L; Zheng Y; Qi Z; Liang H; Liu Y; Hong K; Shao Y
    Vaccine; 2012 Aug; 30(36):5316-23. PubMed ID: 22749599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination.
    Torrents de la Peña A; de Taeye SW; Sliepen K; LaBranche CC; Burger JA; Schermer EE; Montefiori DC; Moore JP; Klasse PJ; Sanders RW
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29367243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
    Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
    Front Immunol; 2020; 11():984. PubMed ID: 32582155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.
    Fu M; Hu K; Hu H; Ni F; Du T; Shattock RJ; Hu Q
    Vaccine; 2019 Dec; 37(51):7501-7508. PubMed ID: 31564450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.
    Liu L; Hao Y; Luo Z; Huang Y; Hu X; Liu Y; Shao Y
    Vaccine; 2012 Jun; 30(28):4135-43. PubMed ID: 22561314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
    Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
    J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.
    Bricault CA; Yusim K; Seaman MS; Yoon H; Theiler J; Giorgi EE; Wagh K; Theiler M; Hraber P; Macke JP; Kreider EF; Learn GH; Hahn BH; Scheid JF; Kovacs JM; Shields JL; Lavine CL; Ghantous F; Rist M; Bayne MG; Neubauer GH; McMahan K; Peng H; Chéneau C; Jones JJ; Zeng J; Ochsenbauer C; Nkolola JP; Stephenson KE; Chen B; Gnanakaran S; Bonsignori M; Williams LD; Haynes BF; Doria-Rose N; Mascola JR; Montefiori DC; Barouch DH; Korber B
    Cell Host Microbe; 2019 Jan; 25(1):59-72.e8. PubMed ID: 30629920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
    Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
    Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.